

# CONGENITAL CARDIOLOGY TODAY

Timely News and Information for BC/BE Congenital/Structural Cardiologists and Surgeons

Volume 8 / Issue 7

July 2010

North American Edition

## IN THIS ISSUE

### Stent Therapy for Clotted Blalock-Taussig Shunts

by Emmanouil Tsounias, MD and  
P. Syamasundar Rao, MD  
~Page 1

### Is There a Need for a North American Pediatric Cardiology Organization?

by Robert Campbell, MD and  
Robert Shaddy, MD  
~Page 10

### Hybrid Procedures: Evolution of Change in Managing Congenital Heart Disease

by Sharon L. Hill, MSN, ACNP;  
John P. Cheatham, MD; Ralf J. Holzer,  
MD, MSc; Alistair Phillips, MD and  
Mark Galantowicz, MD  
~Page 11

### Abstracts from "The Evolving Concepts in the Management of Complex Congenital Heart Disease II" - Part IV

~Page 18

## DEPARTMENTS

### August / September 2010 Medical Meeting Focus: ISHAC

~Page 9

### Medical News, Products and Information

~Page 22

## CONGENITAL CARDIOLOGY TODAY

Editorial and Subscription Offices

16 Cove Rd, Ste. 200

Westerly, RI 02891 USA

[www.CongenitalCardiologyToday.com](http://www.CongenitalCardiologyToday.com)

© 2010 by Congenital Cardiology Today  
ISSN: 1544-7787 (print); 1544-0499  
(online). Published monthly. All rights  
reserved.

Statements or opinions expressed in  
Congenital Cardiology Today reflect the  
views of the authors and sponsors, and  
are not necessarily the views of  
Congenital Cardiology Today.

## Stent Therapy for Clotted Blalock-Taussig Shunts

By Emmanouil Tsounias, MD and  
P. Syamasundar Rao, MD

### INTRODUCTION

Patients with large inter-ventricular communication and severe right ventricular outflow obstruction, including pulmonary atresia, require surgical intervention. Corrective surgery, when feasible, is the preferred treatment option. When total correction is not feasible, either because of the age and size of the patient at presentation or because of anatomic complexity, surgical palliation with a variety of aorto-pulmonary shunts (reviewed elsewhere<sup>1</sup>) is undertaken. Subclavian artery to ipsilateral pulmonary artery anastomosis, first described by Blalock and Taussig<sup>2</sup> stood the test of time and became a standard mode of therapy. More recently, insertion of an interposition Gore-Tex graft (W.L. Gore & Associates, Inc., Flagstaff, AZ) between the subclavian artery and ipsilateral pulmonary artery, commonly referred to as modified Blalock-Taussig (mBT) shunt, described by deLeval et al,<sup>3</sup> has become the procedure of choice. In patients with single ventricle physiology, palliation with first stage Norwood procedure is performed; in such patients, mBT shunt is commonly used to provide pulmonary blood flow.

Complete or partial obstruction of these shunts can occur causing acute hypoxemia or, in more severe cases, shock and

collapse. If stenosis or obstruction develops before planned surgical correction, additional palliative surgery may be necessary thus increasing morbidity and inter-stage mortality. The objectives of this presentation are to describe our experience with percutaneous implantation of stents in the Gore-Tex grafts to successfully palliate infants with blocked mBT shunts and to discuss the management issues related to this subject.

***"Patients with large inter-ventricular communication and severe right ventricular outflow obstruction, including pulmonary atresia, require surgical intervention. Corrective surgery, when feasible, is the preferred treatment option."***

### MATERIAL AND METHODS

Between December 2004 and January 2008, three infants (2 males, 1 female; 12 days to 4 months of age; median weight of 4 Kg), two

First Class Mail  
U.S. Postage  
**PAID**  
Hagerstown MD  
Permit No. 93

### Recruitment Ads

Pages: 6, 8, 14, 16, 19, 20 22 and 23



# ELECTRIFYING OPTIONS

# BIS

Z-Med<sup>tm</sup>  
Tyshak<sup>®</sup>  
Z-Med II<sup>tm</sup>  
Tyshak<sup>®</sup> II  
Mini Ghost<sup>tm</sup>  
Multi-Track<sup>tm</sup>  
COEfficient<sup>tm</sup>  
Tyshak<sup>®</sup> Mini  
Inflation Device  
Atrioseptostomy



B. Braun Interventional Systems Inc.

824 12th Ave. | Bethlehem, PA 18018 | Ph: 1-877-VENA CAV (836-2228) | Fax: 1-610-266-3982

[www.bbraunusa.com](http://www.bbraunusa.com)



**Table I. Summary of Cases Undergoing Stent Therapy for Thrombosis of BT Shunt**

	Case #1	Case #2	Case #3
Primary Diagnosis	TOF	HLHS	HLHS
Age at Shunt Surgery	14 Days	7 Days	7 Days
Shunt (Gore-Tex graft) Diameter	5 mm	4 mm	4 mm
Time to Occlusion	28 days	5 days	3.5 months
Weight at Stent Implantation	4.9 Kg	4.0 Kg	4.0 Kg
Preceding Thrombolysis	Yes	Yes	Yes
Preceding Balloon Angioplasty	Yes	No	Yes
Stent Type Size (mm)	Express II (Scimed) Diameter: 5; Length: 16	Driver (Medtronic) Diameter: 4; Length:15	Driver (Medtronic) Diameter: 4; Length:15
Percent increase in Arterial O <sub>2</sub> Saturation Following Stent Deployment	40%	40%	41%
Patency of Stent by Angiography Immediately After Stent Placement	Widely Patent (Figure 1D)	Widely Patent (Figure 2F)	Widely Patent (Figure 3D)
Follow-up Shunt Patency	Patent – 6 months – Echo	Patent – 6 months – Echo & Angiogram	Patent – 2 months – Echo & Angiogram
Follow-up Outcome	Lost to Follow-up	Bidirectional Glenn	Bidirectional Glenn
BT, Blalock-Taussig; Echo, Echo-Doppler study; HLHS, Hypoplastic Left Heart Syndrome; O <sub>2</sub> , oxygen; TOF, Tetralogy of Fallot.			

with Hypoplastic Left Heart Syndrome (HLHS) and one with Tetralogy of Fallot (TOF) with pulmonary atresia were referred for emergency transcatheter recanalization of the mBT shunts (Table I) for severe life threatening hypoxia (oxygen saturation <40%), with acute shunt occlusion not responsive to pharmacologic thrombus dissolution. Indications for the procedure were severe hypoxemia, metabolic acidosis, hypotension and shock. The technique involved initially defining the angiographic anatomy, followed by mechanical recanalization and access of the shunt beyond the stenotic region using soft tipped guide wires and right coronary artery (RCA) catheters (Cook, Bloomington, IN). Four to 5 mm-diameter (15 to 16 mm-long) premounted stents (Driver [Medtronic, Minneapolis, MN] or Express II [Scimed, Maple Grove, MN]) were positioned within the Gore-Tex graft

of the mBT shunt and the balloon inflated, thus implanting the stents. Post stent oxygen saturations and angiograms were recorded and compared with those obtained prior to stent. Immediate success is defined as improvement in arterial oxygen saturation to 75% or higher. Success at follow-up is defined as the infant reaching the age and size suitable for next stage palliation (bidirectional Glenn in HLHS patients) or corrective surgery (total correction of TOF patients).

#### CASE REPORTS

**Case # 1.** This is a six week old male infant with pulmonary atresia, a large ventricular septal defect, right aortic arch and a small patent ductus arteriosus who underwent a left mBT shunt at age two weeks. He did well in the post operative period. During fundoplication and gastric

tube placement four weeks later, the patient developed hypoxemia and hypotension with ensuing cardiac arrest; he was successfully resuscitated. Patient was started on PGE<sub>1</sub> infusion which resulted in minimal increase in the oxygen saturation. Echocardiogram revealed complete occlusion of the mBT shunt. The patient was taken to the Cardiac Cath Lab and a left subclavian artery cineangiogram was performed which revealed complete blockage of the mBT shunt. Mechanical thrombolysis with RCA catheter and guide wires was performed. Then balloon angioplasty of the mBT shunt with a 6-mm diameter balloon was performed, followed by local heparin infusion for 24 hours. Repeat cineangiograms the next day revealed sub-total occlusion of the shunt (Figure 1A). A 5-mm diameter, 16-mm long balloon expandable Express II stent (Scimed) was selected for implantation.


## United States and Canada Pediatric Cardiologists, Congenital Heart Surgeons in Hospitals Providing Open Heart Surgery for Children 2008/2009

*Compiled by Dilip R. Bhatt, MD, FAAP; Kenneth Jue, MD, FAAP; Janice Stillwell (Project Manager)*

*This Directory is available in a PDF file: [www.CongenitalCardiology.com/DIR2008.pdf](http://www.CongenitalCardiology.com/DIR2008.pdf):*

Published by


**CONGENITAL CARDIOLOGY TODAY**



**Figure 1 (Case #1).** A. Selected cineangiographic frame from subclavian artery injection demonstrating stenotic and almost completely obstructed (arrowhead S) Blalock-Taussig shunt. B. A guide wire has been passed through Blalock-Taussig shunt and its tip positioned in the distal right pulmonary artery over which an unexpanded stent (St) is placed within the Blalock-Taussig shunt. C. Same as B except that the stent-covered balloon (Ball) is inflated. D. Post-stent implantation angiogram showing the well opacified, widely patent stent (St) in the modified Blalock-Taussig shunt with subsequent opacification of the branch pulmonary arteries.

The shunt was successfully cannulated using 4 French right coronary artery (RCA) catheter and a 0.035" Benston straight guide wire. A 0.014 hi torque Spartacore guide wire (Guidant, St. Paul, MN) was positioned into the distal lower lobe branch of the right pulmonary artery and the right coronary artery catheter removed. The selected balloon-mounted stent catheter was introduced over the wire and positioned across the mBT shunt (Figure 1B). The balloon was then inflated up to 16 atm of pressure (Figure 1C), thus implanting the stent. Repeat cineangiogram revealed a wide open stent with good flow (Figure 1D) into the pulmonary arteries. The oxygen saturations improved to 80%. Following return to the observation unit, heparin, 50 units/Kg as bolus was given intravenously, followed by heparin drip of 20 units/Kg/hour and PTT maintained at 1.5 to 2X normal by adjusting heparin dose. The heparin was discontinued 48 hours later. Aspirin (40.5 mg) was continued and the baby discharged home a week later. Follow-up evaluation one and six months after discharge revealed good oxygen saturations (85%), no signs of heart failure and wide open shunt on echo-Doppler studies. The baby was lost to further follow-up.

**Case # 2.** A 12-day old female infant with complex congenital heart disease (forme fruste HLHS) including a single ventricle with mitral



**Figure 2. (Case #2)** A. Selective right innominate artery cineangiographic frame demonstrating complete blockage of the BT shunt; note radiolucent mass (Thrombus - Thr) marked with arrowhead. B. Following mechanical thrombolysis, partial recanalization of the Blalock-Taussig (BT) shunt was seen. C. Selected cineradiographic frame showing a hi-torque floppy guide wire placed across the Gore-Tex graft into pulmonary artery. D. The stent (St) was advanced over the wire and positioned within the Gore-Tex graft. E. Selected cineradiographic frame demonstrating inflated stent-mounted balloon (Ball) in the Gore-Tex graft. F. Selected right innominate artery cineangiographic frame showing opacification of the stent (St) and both branch pulmonary arteries.

atresia, hemitruncus with left pulmonary artery arising from the ascending aorta and multiple aorto-pulmonary collateral arteries (MAPCAs), underwent unifocalization along with a right mBT shunt using 4-mm diameter Gore-Tex graft at age 7-days. On the 5th post-operative day, while about to be transferred to intermediate care unit, the baby suddenly developed severe cyanosis with an oxygen saturation of 40%. Echo-Doppler study did not demonstrate Doppler flow in the BT shunt. While waiting to be transferred to the Cath Lab, medical therapy including volume expanders, inotropic support, 100% oxygen and nitric oxide and recombinant tissue

plasminogen activator (r-tPA) administration increased the oxygen saturations to low 60s. Selective cineangiography revealed complete blockage of the BT shunt (Figure 2A). Mechanical thrombolysis with a RCA catheter and a 0.035" removable core straight tip guide wire was performed. Repeat cineangiogram (Figure 2B) revealed some dissolution of the thrombus. The mBT shunt graft measured 13.4 mm x 3.4 mm diameter. Based on these data, a 4 mm-diameter, 15 mm long Driver (Medtronic) stent was selected for implantation. Initially, a hi-torque floppy guide wire was placed across the Gore-Tex graft into the pulmonary artery (Figure 2C). The stent was advanced over the wire (Figure 2D) and based on fixed landmarks, the stent position was verified and the balloon was inflated (Figure 2E) twice, initially for 10 sec at 10 atm. pressure, then for 6 seconds at 13 atm. pressure. Once the stent was successfully deployed, the oxygen saturations improved to 80%. The stent delivery catheter was removed and a 4-French multipurpose catheter was positioned proximal to the stent and an angiogram was performed which revealed wide open mBT shunt with opacification of both pulmonary arteries (Figure 2F). Anticoagulation with heparin followed by aspirin, as in the first case, was instituted. Follow-up echocardiograms one and five months later, as well as an angiogram at six months of age revealed wide-open shunt. The patient had bidirectional Glenn at the age of six months.

**Case # 3.** A 4-month old male with forme fruste Hypoplastic Left Heart Syndrome, Shone's variant, coarctation of the aorta, mesocardia and s/p Damus-Kaye-Stansel/Norwood procedure with

a right mBT shunt (4 mm-diameter Gore-Tex graft) at age 7 days, presented to the emergency room with severe cyanosis and had an oxygen saturation of 37%. Echocardiogram revealed the mBT shunt to be completely occluded, without evidence of flow through the shunt and no flow into the pulmonary arteries. An aorto-pulmonary collateral vessel provided minimal blood supply to the lungs. The patient was started on r-tPA (initially 0.1 mcg/kg/min and was later increased to 0.3 mcg/kg/min) and was taken to the Cath Lab approximately 24 hours later to evaluate the shunt. Transvenous aortic arch angiography revealed completely occluded mBT shunt, presumably thrombosed. Pulmonary venous wedge angiography revealed small but patent distal pulmonary arteries (Figure 3A). A collateral vessel from the descending aorta to left lower lobe was seen (not shown). Despite multiple attempts, we were unable to advance a wire through or around the thrombus. The patient was restarted on r-tPA and heparin was added. Repeat cardiac catheterization was performed the next day via right common carotid artery cut-down. Cineangiograms revealed partially occluded mBT shunt which measured 13.2 mm x 1.7 mm. A 4-French multipurpose catheter was placed proximal to the shunt. Rapid to and fro movement of the Benston straight guide wire in and out of the shunt, as well as vigorous catheter manipulation to disrupt the clot to improve flow across the shunt, was undertaken. Recanalization was partially achieved by mechanical clot disruption (Figure 3B). A 4 mm-diameter, 15 mm-long Driver stent (Medtronic) was selected for implantation. The catheter was advanced into the pulmonary artery and the guide wire was removed. A Choice PT Extra Support guide wire (Boston Scientific, Natick, MA) was introduced and the catheter was removed. The selected balloon-mounted Driver stent was introduced over the wire, through the carotid arterial sheath and positioned across the mBT shunt. The balloon was inflated at 9 atm of pressure thus deploying the stent (Figure 3C). Follow-up cineangiograms revealed wide open stent with good flow (Figure 3D) and improved O<sub>2</sub> saturations (78%). He underwent bidirectional Glenn procedure two months later.


## RESULTS

In summary, successful stent implantation into the BT shunt was performed in all cases; thus the technical success rate was 100%, with complete revascularization of all stented shunts (Table I). No procedural complications were encountered. There was no acute in-stent re-thrombosis, stenosis or stent kinking. Following stent deployment, the oxygen saturations improved to 78 to 80% and the stents implanted were wide open by angiography. No vessel injury or perforation was encountered. The patients did not require immediate or subsequent surgical revision of the stent implanted shunt. Two HLHS patients underwent subsequent bidirectional Glenn procedures, and the patient with TOF and pulmonary atresia was lost to follow-up.

## DISCUSSION

As mentioned in the introduction section, surgical aorto-pulmonary shunts are performed if total surgical correction of a given cyanotic heart defect with pulmonary oligemia is not feasible. Modified BT shunts<sup>3</sup> are most commonly used for this purpose. Similarly, mBT shunts<sup>3</sup> are also used in Norwood palliation of HLHS patients although some surgeons use Sano shunts.<sup>4</sup>

**Causes of Obstruction.** Obstruction of such surgical stents can occur, causing hypoxemia. While causes of such obstruction are not clearly understood, it may be related to thrombosis, suture line scar formation and stricture, neo-intimal proliferation and vascular distortion/stenosis due to surgery or constriction of ductal tissue remnants or a combination thereof. Administration of platelet-inhibiting doses of aspirin to prevent thrombosis of the shunts has long been in practice and all three of our patients have been on aspirin.



**Figure 3.** (Case #3) A. Pulmonary venous wedge cineangiographic frame demonstrating pulmonary arteries (PA). B. Following r-tPA for 24 hours and mechanical thrombolysis, the shunt (CI BT) is partially open with radiolucent clots. The position of the guide wire (GW) across the BT shunt into the left pulmonary artery is also shown. C. Cineradiographic frame showing the implanted stent (St). The guide wire (GW) is still in place. D. Post-stent implantation cine angiographic frame demonstrating wide-open stent (St) with good opacification both the right (RPA) and left (LPA) pulmonary arteries.





## Think about why you wanted to be a doctor in the first place...

Our co-founder, Dr. Thomas Frist, Sr. said, "Bettering the human condition is the greatest good any individual can achieve." More than likely, you decided to get into Pediatrics because you could make a difference in the lives of the children you'd care for. You'd do your part by taking care of our most precious commodity, the children who will be our future. Now... let us do our part by helping you find your dream job in one of our communities.

We are the largest healthcare company in the US...with over 160 hospitals in 20 states. Whether you're looking for a place to start, or somewhere to complete a successful career, chances are we have something that will fit.



### CURRENT OPPORTUNITIES AVAILABLE IN PEDIATRIC CARDIAC MEDICINE

- Pediatric CV Surgeon – Dallas and Oklahoma City
- Clinical/Diagnostic Pediatric Cardiologists – Wichita, San Antonio, Dallas, Oklahoma City, Denver
- EP Pediatric Cardiologist – Tulane University

Kathy Kyer  
Pediatric Subspecialty Recruitment Manager  
kathleen.kyer@HCAHealthcare.com  
937.235.5890

**Clinical Features.** Disappearance of a previously documented continuous murmur and a fall in arterial oxygen saturation are indicative of shunt occlusion, especially if the shunt is the only or the major source of pulmonary blood flow. Echo-Doppler studies using pulsed and continuous wave Doppler interrogation and color flow mapping are useful in the evaluation of the patency of the shunt. Selective innominate/subclavian artery angiography is confirmative.


**Management Options.** If stenosis or occlusion of the Blalock-Taussig (BT) shunt develops prior to the planned surgical correction or bidirectional Glenn procedure, additional palliative surgery may become necessary. In such situations, transcatheter intervention to relieve the obstruction should be considered. Balloon dilatation of the narrowed BT shunt, first described by Fisher et al,<sup>5</sup> is an option; they reported improvement in oxygen saturation from 68 to 80% following balloon angioplasty of BT shunt in a 4-year-old child. Subsequently, a number of cardiologists, including our group<sup>6</sup> have reported on the experience with balloon angioplasty of both classic and modified BT shunts, reviewed elsewhere.<sup>7-9</sup> The majority of this experience is with dilating stenotic lesions that develop months or years after the creation of BT shunts, and may not be truly applicable to acutely clotted shunts that are being addressed in this report. Furthermore, balloon angioplasty is not uniformly effective<sup>9,10</sup> and some develop restenosis with time. Placement of stents across the stenosed or occluded BT shunts to ensure their patency appears to be an attractive option.

Management of acutely clotted shunts in the past was largely limited to surgical shunt revision. Less invasive methods such as pharmacological thrombolysis,<sup>11-17</sup> mechanical thrombolysis,<sup>18,19</sup> balloon angioplasty<sup>19-27</sup> and placement of stents<sup>27-36</sup> and a combination thereof are increasingly used in the initial treatment. Successful use of fibrinolytic therapy with r-tPA or streptokinase in the treatment of thrombosed BT shunts has been reported.<sup>11-17</sup> However, the risk of bleeding complications, especially if reoperation is required, and failure of fibrinolytic therapy, requiring reoperation suggest that fibrinolytic therapy may not be ideal for use in early postoperative period. While balloon angioplasty has been used with success,<sup>19-27</sup> several patients required stent placement to adequately address the shunt occlusion. Moszura et al<sup>36</sup> reviewed their experience with recanalization of shunt thrombosis/occlusion in 23 patients; 14 of these were acute occlusions. Balloon angioplasty with or without local r-tPA administration was undertaken in 22 of 23 patients with improvement. However, three of their patients required stent implantation.

**Stent Therapy.** Zahn and his colleagues<sup>28</sup> were the first to report stent implantation to successfully treat a thrombosed mBT shunt; they implanted a Palmaz-Schatz (Johnson & Johnson Interventional Systems Co., Warren, NJ) stent in an 8-day old baby with HLHS who developed shunt thrombosis following Norwood procedure in less than 24 hours after surgery. The oxygen saturation improved by 42% following stent deployment. No additional interventions were necessary until bidirectional Glenn procedure at the age six months. Subsequently a number of interventional cardiologists reported use of the stents to treat acutely thrombosed mBT shunts.<sup>27,29-36</sup>

Deployment of stents for treating obstructions that develop shortly after surgical creation of shunt<sup>27-36</sup> as well as those that occur during follow-up<sup>31,34,36,37</sup> appears possible. Implantation of stents is feasible and effective in thrombotic, obstructive lesions that develop spontaneously<sup>28-31, 33-36</sup> and those that develop after catheter

For information on PFO detection go to: [www.spencertechnologies.com](http://www.spencertechnologies.com)



manipulation within the shunt.<sup>32</sup> Successful treatment is possible in obstructive lesions at proximal<sup>31,34,37</sup> or distal<sup>27,31</sup> anastomotic sites, as well as those in mid-portion of the graft secondary to intimal proliferation.<sup>37</sup> Stent therapy appears feasible and effective in mBT shunts,<sup>27-36</sup> classic BT shunts,<sup>31</sup> central aorto-pulmonary Gore-Tex grafts<sup>35,38</sup> and Sano shunts.<sup>27,34,35,39</sup> The experience with cases described in the current report supplements that described previously<sup>27-36</sup> in relieving hypoxemia secondary to acutely clotted BT shunts.

**Technique.** The procedure involves initially defining the site and extent of obstruction by selective cine-angiograms from the innominate or subclavian artery (Figures 1A and 2B). Probing the shunt using angled catheters (RCA, Cobra, cut-pigtail or angled glide) and soft-tipped straight guide wires (Straight Benston, removable-core straight Amplatz, glide or Woolley guide wires) to produce mechanical thrombolysis may be helpful in at least partial recanalization of the thrombosed shunt. Adequate anticoagulation should precede these maneuvers. The shunt should then be crossed with a soft-tip floppy wire over which balloon catheters (same size as the Gore-Tex graft diameter) are inserted and balloon dilatation performed. If there is not an adequate increase in oxygen saturation or angiography shows significant residual thrombus (Figures 1A, 2B and 3B), stent implantation should be undertaken. The currently available coronary stents track well over the coronary guide wires. Some interventionalists<sup>27,31,34</sup> use long sheaths to position the stents; this may result in hemodynamic instability and femoral arterial complications. We have had success in delivering these stents via short 4-French sheaths in the femoral artery (Figures 1B and 2D). Stent deployment should be followed by selective cineangiography to demonstrate the patency of the stented shunts (Figures 1D, 2F and 3D). While we have utilized fibrinolytic agents such as r-tPA prior to the procedure, administering locally with a catheter left in place for an extended period of time, in some of our patients, there is no unanimity of opinion regarding their use. Based on lack of success in our cases we do not advocate their routine use. However, anticoagulation with heparin drip following stent implantation followed by aspirin is recommended by most interventionalists.

**Additional Considerations.** Infusion of prostaglandin E<sub>1</sub> (PGE<sub>1</sub>) in neonates may help open the ductus which may improve the oxygen saturation. Addressing the proximal stenosis (of the subclavian<sup>40</sup> or innominate<sup>31</sup> artery) and branch pulmonary artery stenosis<sup>10,31,34,36</sup> either by balloon angioplasty or stent implantation is important to ensure the patency of the stented shunt and to provide adequate pulmonary blood flow.

Apart from stent implantation into the occluded shunt, alternative solutions such as stenting the stenosed aorto-pulmonary collateral vessels,<sup>37,41</sup> stenting of the right ventricular outflow tract,<sup>26,36</sup> balloon valvuloplasty of the pulmonary valve<sup>31,42</sup> and radiofrequency or blunt guide wire perforation of the atretic pulmonary valve<sup>43-46</sup> should also be considered with the intent to augment pulmonary blood flow when managing these hypoxemic infants. However, the use of such procedures should be in accordance with achieving long-term goals of biventricular correction or separation of circuits by Fontan route, as the case may be.

**Recommendations.** In our patient cohort, we initially infused heparin or r-tPA to dissolve the clots for 24 hours prior to going to the Cath Lab, performed mechanical thrombolysis including balloon angioplasty and administered heparin and/or r-tPA with the catheter tip placed close to the shunt and none were effective. Deployment of stents appears to have achieved the best and most lasting result. Based on this experience we would recommend mechanical thrombolysis with the catheters/guide wires used for cannulation of the mBT shunt (to reduce the clot burden) followed by balloon angioplasty, and if that is not successful, stent placement at the same sitting for treatment of hypoxemia secondary to acute thrombosis of BT shunts. Alternative

ways to augment pulmonary blood flow such as stenting the stenosed aorto-pulmonary collateral vessels, stenting of the right ventricular outflow tract, balloon dilatation of stenotic pulmonary valve and guide wire perforation of atretic pulmonary valve, as alluded to above, should also be entertained when dealing with hypoxemic infants secondary to pulmonary oligemia.

Much larger experience than is reported thus far, further miniaturization stent delivery systems, and greater flexibility of the stents to pass through tortuous courses may further improve feasibility, safety and effectiveness of this mode of therapy.

## CONCLUSIONS

The experience in stenting aorto-pulmonary shunts, though limited, appears feasible, safe and effective. Improvement in oxygen saturation, the primary objective, was achieved in all our cases. The procedure, though labor intensive, is a useful technique in alleviating hypoxemia and allowing the patient to reach the next step palliation of their complex cyanotic congenital heart disease.

**Acknowledgement.** The authors wish to thank and acknowledge the contributions to the clinical care of the reported patients by the members of the Divisions of Pediatric Cardiology and Pediatric Cardiovascular Surgery at UT-Houston Medical School, Houston, Texas.

## REFERENCES

1. Rao PS, Covitz W, Chopra PS. Principles of palliative management of patients with tricuspid atresia. In: Rao PS (ed.) Tricuspid Atresia, 2nd ed. Futura Publishing Co, Mount Kisco, NY, 1992, pp.297-320
2. Blalock A, Taussig HB. The surgical treatment of malformations of the heart in which there is pulmonary stenosis or atresia. JAMA 1945; 128:189-202.
3. deLeval M, McKay R, Jones M, et al. Modified Blalock-Taussig shunt: Use of subclavian orifice as a flow regulator in prosthetic systemic-pulmonary artery shunts. J Thorac Cardiovasc Surg 1981; 18:112-9.
4. Sano S, Ishino K, Kawada M, et al. Right ventricle-to-pulmonary artery shunt in first-stage palliation of hypoplastic left heart syndrome. J Thorac Cardiovasc Surg 2003; 126:504-10.
5. Fischer DR, Park SC, Neches WH, et al. Successful dilatation of stenotic Blalock-Taussig anastomosis by percutaneous transluminal balloon angioplasty. Am J Cardiol 1985; 55:861-2.
6. Rao PS, Levy J, Chopra PS. Balloon angioplasty of stenosed Blalock-Taussig anastomosis: role of balloon-on-wire in dilating occluded shunts. Am Heart J 1990; 120:1173-8.
7. Rao PS. Transcatheter management of cyanotic congenital heart defects: A review. Clin Cardiol 1992; 15:483-96.
8. Rao PS. Transcatheter treatment of pulmonary outflow tract obstruction: A review. Progress Cardiovasc Dis 1992; 35:119-58.
9. Rao PS. Concurrent balloon dilatation of stenosed aorto-pulmonary Gore-Tex shunts and branch pulmonary arteries (Editorial). J Am Coll Cardiol 2001; 37:948-50.
10. Wang J, Wu M, Chang C, et al. Balloon angioplasty of obstructed modified systemic pulmonary artery shunts and pulmonary artery stenosis. J Am Coll Cardiol 2001; 37:940-7.
11. Batchvarova V, Daskalov E, Morosova A. Fibrinolytic treatment. First results during the early postoperative period. Arch Mal Coeur Vaiss 1979; 72:1376-8.
12. LeBlanc JG, Culham JA, Chan KW, et al. Treatment of grafts and major vessel thrombosis with low-dose streptokinase in children. Ann Thorac Surg 1986; 41:630-5.
13. Rajani RM, Dalvi BV, Kulkarni HL, Kale PA. Acutely blocked Blalock-Taussig shunt following cardiac catheterization: Successful recanalization with intravenous streptokinase. Am Heart J 1990; 120:1238-9.
14. Ries M, Singer H, Hofbeck M. Thrombolysis of a modified Blalock-Taussig shunt with recombinant tissue plasminogen activator in a



- newborn infant with pulmonary atresia and ventricular septal defect. *Br Heart J* 1994; 72:201–2.
15. Klinge J, Hoffbeck M, Ries M, et al. Thrombolysis of modified Blalock-Taussig-shunts in infancy with recombinant plasminogen activator. *Z Kardiol* 1995; 84:476–80.
  16. Malm TK, Holmqvist C, Olsson CG, et al. Successful thrombolysis of an occluded modified Blalock shunt three days after operation. *Ann Thorac Surg* 1998; 65:1453–5.
  17. Santos de Soto J, Menendez GN, Soult RJA, et al. Fibrinolytic treatment with tissue plasminogen activator in a thrombosed modified Blalock–Taussig shunt. *Rev Esp Cardiol* 2001; 54:1113–5.
  18. Kokov LS, Korostelev AN, Grinko AN, et al. Recanalization and thrombectomy of internal anastomosis in patient with tetralogy of Fallot using the AngioJet rheolytic catheter. *Cathet Cardiovasc Interv* 2001; 53:504–7.
  19. Ormiston JA, Neutze JM, Calder AL, et al. Percutaneous balloon angioplasty for early postoperative modified Blalock Taussig shunt failure. *Cathet Cardiovasc Diagn* 1993; 29:31–4.
  20. Sreeram N, Walsh K, Peart I. Recanalization of an occluded modified Blalock Taussig shunt by balloon dilatation. *Br Heart J* 1993; 70:474–5.
  21. Galal MO, Attas K, Baslaim G. Recanalization of an occluded modified Blalock–Taussig shunt by balloon angioplasty within 12 hours of its construction. *Cardiol Young* 2000; 10:641–3.
  22. Chessa M, Piazza L, Butera G, et al. Images in cardiovascular medicine. Transcatheter balloon recanalization of an occluded modified Blalock–Taussig shunt. *Ital Heart J* 2003; 4:285.
  23. Singh V, Pillai S, Kulkarni S, et al. Thrombolysis with percutaneous transluminal balloon angioplasty of a blocked modified Blalock–Taussig shunt. *Indian Heart J* 2004; 56:673–6.
  24. MacMillan M, Jones TK, Lupinetti FM, et al. Balloon angioplasty for Blalock–Taussig shunt failure in early postoperative period. *Cathet Cardiovasc Interv*. 2005; 66:585–9.
  25. Kogon B, Villari C, Shah N, et al. Occlusion of the modified Blalock–Taussig shunt: Unique methods of treatment and review of catheter-based intervention. *Congenit Heart Dis* 2007; 2:185–90.
  26. Sreeram N, Emmel M, Ben-Mime L, et al. Transcatheter recanalization of acutely occluded modified systemic to pulmonary artery shunts in infancy. *Clin Res Cardiol* 2008; 97:181–6.
  27. Gillespie MJ, Rome JJ. Transcatheter treatment for systemic-to-pulmonary artery shunt obstruction in infants and children. *Catheter Cardiovasc Interv* 2008; 71:928–35.
  28. Zahn EM, Chang AC, Aldousany A, et al. Emergent stent placement for acute Blalock-Taussig shunt obstruction after stage I Norwood surgery. *Cathet Cardiovasc Diagn* 1997; 42:191–4.
  29. Peuster M, Fink C, Bertram H, et al. Transcatheter recanalization and subsequent stent implantation for the treatment of early postoperative thrombosis of modified Blalock-Taussig shunts in two children. *Cathet Cardiovasc Diagn* 1998; 45:405–8.
  30. Sivakumar K, Anil SR, Ravichandra M, et al. Emergency transcatheter balloon recanalization of acutely thrombosed modified Blalock–Taussig shunts. *Indian Heart J* 2001; 53:743–8.
  31. Lee KJ, Humpl T, Hashmi A, et al. Restoration of aortopulmonary shunt patency. *Am J Cardiol* 2001; 88:325–8.
  32. Tomita H, Hayashi G, Echigo S. "Bail-out" stenting for acute obstruction of a modified Blalock-Taussig shunt following selective angiography. *Cardiol Young*. 2002 ;12:496–8.
  33. Moszura T, Ostrowska K, Dryzek P, et al. Thrombolysis and stent implantation in a child with acute occlusion of the modified Blalock–Taussig shunt – a case report. *Kardiol Pol* 2004; 60:354–6.
  34. Petit CJ, Gillespie MJ, Kreutzer J, et al. Endovascular stents for relief of cyanosis in single-ventricle patients with shunt or conduit-dependent pulmonary blood flow. *Cathet Cardiovasc Intervent* 2006; 68:280–6.
  35. Kaestner M, Handke RP, Photiadis J, et al. Implantation of stents as an alternative to reoperation in neonates and infants with acute complications after surgical creation of a systemic-to-pulmonary arterial shunt. *Cardiol Young* 2008; 18:177–84.
  36. Moszura T, Zubrzyckac M, Michalaka KW, et al. Acute and late obstruction of a modified Blalock–Taussig shunt: a two-center experience in different catheter-based methods of treatment. *Interactive Cardiovasc Thorac Surg* 2010; 10: 727–31.



SCHOOL OF MEDICINE  
UNIVERSITY of CALIFORNIA • IRVINE

Presents  
**Sudden Cardiac Arrest in Children and Adolescents:**  
*Diagnosis, Therapy and Prevention*  
**January 14 - 15, 2011**

Disney's Grand Californian Hotel® & Spa  
1600 South Disneyland Drive, Anaheim, CA 92802

Designed for physicians, nurses and other healthcare professionals, this conference will present the current state of the art on topics related to the diagnosis, therapy and prevention of cardiac arrest in young people.

**Topics will include:**

- Clinical syndromes associated with risk of sudden death
- Use of automated external and implantable defibrillators in the young
- Arrhythmias in the young
- Screening, with an emphasis on defining levels of evidence and areas of controversy in management decisions

AMA PRA Category 1 Credit™ for CME will be offered

To register or more information visit

[www.choc.org/cardiacconference](http://www.choc.org/cardiacconference) or call (800) 329-2900



37. El-Said HG, Clap S, Fagan TE, et al. Stenting of stenosed aorto-pulmonary collaterals and shunts for palliation of pulmonary atresia/ventricular septal defect. *Cathet Cardiovasc Intervent* 2000; 49:430-6.
38. Alcibar J, Cabrera A, Martinez P, et al. Stent implantation in a central aorto-pulmonary shunt. *J Invasive Cardiol* 1999; 11:506-9.
39. Eicken A, Genz T, Sebening W. Stenting of stenosed shunts in patients after a Norwood-Sano operation. *Cathet Cardiovasc Intervent* 2006; 68:301-3.
40. Peuster M, Fink C, Windhagen-Mahnert B, et al. Early postoperative failure of a modified Blalock-Taussig-Shunt: Successful therapy with angioplasty and subsequent implantation of a Palmaz-Schatz stent into the subclavian artery. *Z Kardiol* 2000; 89: 114-7.
41. Brown SC, Eyskens B, Mertens L, et al. Percutaneous treatment of stenosed major aortopulmonary collaterals with balloon dilatation and stenting: What can be achieved? *Heart* 1998; 79:24-8.
42. Rao PS. Pulmonary valve in cyanotic heart defects with pulmonary oligemia. In: *Percutaneous Interventions in Congenital Heart Disease*, Sievert H, Qureshi SA, Wilson N, Hijazi Z (Eds), Informa Health Care, Oxford, UK, 2007, pp 197-200.
43. Siblini G, Rao PS, Singh GK, et al. Transcatheter management of neonates with pulmonary atresia and intact ventricular septum. *Cathet Cardiovasc Diagn* 1997; 42: 395-402.
44. Justo RN, Nykanen DG, Williams WG, et al. Transcatheter perforation of the right ventricular outflow tract as initial therapy for pulmonary valve atresia and intact ventricular septum in the newborn. *Cathet Cardiovasc Diagn* 1997; 40:408-13.
45. Kuhn MA, Mulla NF, Dyar D, et al. Valve perforation and balloon pulmonary valvuloplasty in an infant with tetralogy of Fallot and pulmonary atresia. *Cathet Cardiovasc Diagn*. 1997; 40:403-6.
46. Rao PS. Role of interventional cardiology in the treatment of neonates: Part III. *Congenital Cardiol Today* 2008; 6(2):1-10.

**CCT**

#### **Corresponding Author**



*P. Syamasundar Rao, MD, Professor and Director,  
Division of Pediatric Cardiology  
University of Texas-Houston Medical School  
Children's Memorial Hermann Hospital  
6410 Fannin, UTPB Suite #425  
Houston, TX 77030  
Phone: 713-500-5738; Fax: 713-500-5751*

*P.Syamasundar.Rao@uth.tmc.edu*

*Emmanouil Tsounias, MD  
Division of Pediatric Cardiology  
University of Texas-Houston Medical School  
Children's Memorial Hermann Hospital  
6410 Fannin, UTPB Suite #425  
Houston, TX 77030*

#### **International Symposium on the Hybrid Approach to Congenital Heart Disease**

*with live presentations  
August 31-September 2, 2010  
Columbus, OH USA  
For details and to register go to:  
**hybridsymposium.com***



**AUGUST / SEPTEMBER 2010  
MEDICAL MEETING FOCUS**

#### **The Fifth International Symposium on the Hybrid Approach to Congenital Heart Disease (ISHAC)**

*August 31-September 2, 2010; Columbus, OH USA*

**[www.hybridsymposium.com](http://www.hybridsymposium.com)**

*With live cases*

**Overview:** A two-day Symposium with a one-day skills Workshop. Attendees will learn the latest clinical and research developments in Hybrid therapies from Nationwide Children's Hospital's international faculty. Past ISHAC Symposiums have had faculty and participants from over 34 states, 50 countries, and 6 continents. ISHAC has something for surgeons, cardiologists, anesthesiologists, nurses and nurse practitioners, perfusionists, allied health professionals, and research scientists.

There will be didactic lectures, moderated discussions, live case demonstrations, special lunch presentations, tours of the Hybrid Suites at Nationwide Children's Hospital, and direct access to the faculty for Q & A. This year, procedures will be performed from Hybrid Suites at Rush Medical Center in Chicago, Miami Children's Hospital, and Nationwide Children's Hospital... with special Hybrid procedures broadcast from the University Laboratory Animal Resources Experimental Surgical Suites (ULAR).

**Course Directors:** John P. Cheatham, MD & Mark Galantowicz, MD

**Keynote Speakers:** Philipp Bonhoeffer, MD & John G. Byrne, MD

**Workshop Directors:** Ralf J. Holzer, MD and Alistair Phillips, MD

**Program Co-Director:** Sharon L. Hill, MSN, ACNP-BC

**Program Coordinator:** Karen E. Heiser, PhD

**Perfusion Directors:** Vincent Olshove, CCP; Daniel Gomez, CCP & Thomas J. Preston, CCP

#### **ISHAC will enable participants to:**

- Compare clinical outcomes between Hybrid and traditional approaches to CHD.
- Implement innovative evidence-based approaches to CHD management.
- Utilize research and multi-center outcomes data to determine care options for infants, children and adults with CHD.
- Acquire clinical skills with new Hybrid treatments and devices (Skills Workshop).

**Selected List of Faculty:** Valerie K. Bergdall, DVM; Philipp Bonhoeffer, MD; John G. Byrne, MD; Christopher Caldarone, MD; Mario Carminati, MD; John P. Cheatham, MD; Curt Daniels, MD; Timothy F. Feltes, MD; Mark Galantowicz, MD; Daniel Gomez, CCP; Daniel Gruenstein, MD; Ziyad M. Hijazi, MD; Sharon L. Hill, MSN, ACNP-BC; Ralf J. Holzer, MD; Shengshou Hu, MD; John P. Kovalchin, MD; Pamela A. Lucchesi, PhD; William T. Mahle, MD; Doff McElhinney, MD; Richard G. Ohye, MD; Vincent Olshove, CCP; Carlos Pedra, MD; Simone Fontes Pedra, MD; Thomas J. Preston, CCP; Alistair Phillips, MD; Mark D. Rodefeld, MD; Carlos Ruiz, MD, PhD; Dietmar Schranz, MD; Nikolay V. Vasilyev, MD; Zhen Xu, PhD; Evan Zahn, MD; David Zhao, MD

# Is There a Need for a North American Pediatric Cardiology Organization?

By Robert Campbell, MD and Robert Shaddy, MD

The profession of pediatric cardiology is facing a difficult future. There exist many different practice models within the specialty of pediatric cardiology (e.g., academic, private practice, group practice, etc.). However, there are common missions that unite all of us: clinical care, education, advocacy, and research. In each of these areas, there are constant changes and increasing challenges that require awareness and responsiveness from each of us in order to optimize our ability to accomplish our missions.

As pediatric cardiologists, our organizational representation has generally been through either large pediatric organizations or large cardiology organizations, but no pediatric cardiology organization. Are we, as a profession, ideally represented by these larger organizations such as the *American College of Cardiology*, *American Heart Association*, *American Academy of Pediatrics* and Sub-board of Pediatric Cardiology? Similarly, as the specialty of pediatric cardiology has continued to expand its "superspecialization," many of us have become increasingly involved with organizations that represent each of our specific clinical and/or academic interests. However, since pediatric cardiologists again

***"It is our goal to solicit input from pediatric cardiologists throughout North America as to the level of interest and as to recommendations for the best next steps forward for the establishment of such an organization.... Please complete this survey and share your views: [www.surveymonkey.com/s/KF8NQZ8](http://www.surveymonkey.com/s/KF8NQZ8)"***

represent a small minority of the membership of these organizations, the voice of pediatric cardiologists in such organizations as the *American Society of Echocardiography*, *Heart Rhythm Society*, and the *Society for Pediatric Research*, etc, is limited.

It is our hope that the specialty of pediatric cardiology can engage in a conversation regarding the possibility of establishing a North American pediatric cardiology organization. A similar organization already exists for pediatric hematology/oncology specialists. The *American Society of Pediatric Hematology and Oncology* (ASPHO) serves as a central body for these healthcare professionals. Legislative issues, research, credentialing, fellowship, continuing medical education, staffing opportunities, quality outcomes, etc. are all discussed and defined within the ASPHO.

There are obviously many hurdles that need to be overcome in order to start such an organization. These include:

- finding the time and resources necessary to establish and sustain it;
- defining its organizational structure, and
- clarifying roles and responsibilities of its members, to name a few.

It is our goal to solicit input from pediatric cardiologists throughout North America as to the level of interest and as to recommendations for the best next steps forward for the establishment of such an organization.

**Please complete this survey and share your views:**  
[www.surveymonkey.com/s/KF8NQZ8](http://www.surveymonkey.com/s/KF8NQZ8)

CCT

## Corresponding Author

Robert Campbell, MD  
Children's Healthcare of Atlanta  
Sibley Heart Center Cardiology  
5455 Meridian Mark Rd., Ste. 530  
Atlanta, GA 30342 USA  
Phone: 404-785-1445  
Fax: 404-785-1461

[Campbellr@kidsheart.com](mailto:Campbellr@kidsheart.com)

Robert Shaddy, MD  
Chief, Division of Cardiology  
The Children's Hospital of Philadelphia  
Professor of Pediatrics, University of Pennsylvania School of Medicine  
Philadelphia, PA USA

## Exploring the Need for a North American Pediatric Cardiology Organization Working Group

Robert Anderson, MD  
United Kingdom

Stuart Berger, MD  
Children's Hospital of Wisconsin

Robert Campbell, MD  
Children's Healthcare of Atlanta Sibley Heart Center

Timothy Feltes, MD  
Nationwide Children's Hospital

Daphne Hsu, MD  
Children's Hospital at Montefiore

Jane Newburger, MD  
Children's Hospital of Boston

Andrew Redington, MD  
Hospital for Sick Kids

Philip Saul, MD  
Medical University of South Carolina

Robert Shaddy, MD  
Children's Hospital of Philadelphia

Kenneth Shaffer, MD  
Pediatrix, Austin TX

Richard Simon  
Pediatrix, West Palm Beach, FL

Jeffrey Towbin, MD  
Cincinnati Children's Hospital Medical Center

Join Us in Celebrating Our  
10th Anniversary!

**Barth Syndrome International Scientific, Medical & Family Conference**  
**Renaissance at SeaWorld, Orlando, FL ~ July 26-31, 2010**

Barth Syndrome Clinics: July 27-28, 2010 ~ Scientific/Medical Sessions: July 29-30, 2010 ~ Family Sessions: July 29-31, 2010  
Poster Session ~ Call for Poster Abstracts (Submission Deadline: April 15, 2010)

For more information, please visit: [www.barthsyndrome.org](http://www.barthsyndrome.org)



Keynote Speaker: Douglas C. Wallace, PhD, Center for Molecular and Mitochondrial Medicine & Genetics, University of California at Irvine, Irvine, CA



# Hybrid Procedures: Evolution of Change in Managing Congenital Heart Disease

By Sharon L. Hill, MSN, ACNP; John P. Cheatham, MD; Ralf J. Holzer, MD, MSc; Alistair Phillips, MD and Mark Galantowicz MD

Collaboration between cardiothoracic surgery and interventional cardiology has evolved over the past decade resulting in increased Hybrid procedures and ultimately improved outcomes for patients with congenital heart disease (CHD). Infants with Hypoplastic Left Heart Syndrome (HLHS), muscular ventricular septal defect (MVSD), and complex pulmonary artery stenosis are examples of patients who have benefited from Hybrid procedures. The aim of Hybrid therapy is to combine surgical and interventional techniques in an effort to

decrease morbidity and mortality and lessen the impact of multiple procedures over the lifetime of a patient. Thinking collaboratively “outside the box” has led to decreased invasive procedures (i.e. avoidance of cardiopulmonary bypass, cardioplegic arrest), increased cost effective care, and improved patient outcomes. Within our group, the idea of cardiothoracic surgical and interventional collaborative procedures was first developed over a decade ago by having to share one conventional operating room for all cardiac procedures, surgery and intervention alike, for children with congenital heart disease while a new catheterization lab was being constructed. The teams were forced into a sort of “marriage,” where each service could experience first hand the advantages and disadvantages of each discipline.

## HLHS and Hybrid Stage I Palliation

Collaborative cardiac procedures were initially targeted for neonates born with HLHS. Hybrid Stage I palliation was first performed in our traditional catheterization lab entirely using a percutaneous transcatheter technique to deliver a balloon-expandable PDA stent, perform balloon atrial septostomy, and for placement of intrapulmonary artery “flow restrictors” (AGA Medical, Golden Valley, MN, USA)<sup>1</sup> as a compassionate use device. The 6mm diameter flow restrictors were 7mm in length with two 2mm fenestrations to allow limited flow. Due to the combination of the stiff delivery cable and long sheath which stented open the right heart valves during delivery, and the acute 90 degree turn to the branch pulmonary arteries, this technique was abandoned due to the instability and hemodynamic compromise in HLHS patients. This led to transcatheter intervention involving PDA balloon expandable stent placement followed by balloon atrial septostomy (if needed) in the cardiac catheterization lab, with bilateral banding of the branch pulmonary arteries in the operating room the following day. One millimeter wide bands were cut from 3.5 or 3.0mm Gore-tex tube graft (W.L. Gore & Associates, Flagstaff, AZ, USA) to encircle the left and right branch pulmonary artery before the takeoff of the upper lobe branch. It was discovered that the previously placed PDA stent increased the technical difficulty for the surgeon applying the LPA band. Subsequently, the order of palliation was reversed and all HLHS patients underwent bilateral branch PA banding in the operative suite, followed by PDA stent and BAS in the cardiac catheterization lab. Controlling pulmonary blood flow with the PA bands placed first allowed stabilization of systemic and pulmonary flow and improved hemodynamics. Ultimately, all HLHS patients have undergone Hybrid Stage I palliation with surgical placement of bilateral PA bands followed by direct puncture and sheath placement in the main pulmonary artery for PDA stent placement (now using both self- and balloon-expandable stents) performed off cardiopulmonary bypass through a limited sternotomy incision.<sup>2</sup> This technique eliminated going through the right heart and crossing the tricuspid and pulmonary valves. A BAS was performed at a later date if needed. The palliative procedure started in the traditional operating room with portable X-Ray imaging (Figure 1), moved to specially designed Hybrid Cardiac Catheterization Suites (Figure 2), and now is equally performed in the Hybrid Cardiac Operating Suite (Figure 3). This technique has now been perfected and reproducible throughout many centers, even in high risk HLHS weighing <2.5kg.<sup>2-6</sup> In our own center, babies as small as 1.0kg have had successful Hybrid Stage I palliation, Comprehensive Stage II repair, and Fontan completion .... a feat unfathomable in 1980 in Dr. Norwood's original report (Figure 4).

## Perventricular Device Closure of MVSD

A Hybrid approach for successful perventricular device closure of MVSD is dependent upon a collaborative effort between the



Figure 1. Hybrid Stage I palliation for HLHS in a traditional operating room with portable X-Ray imaging.



Figure 2. Same procedure performed in the Hybrid Cardiac Catheterization Suite.



Figure 3. The newer Hybrid Cardiac Operative Suite is well suited for Hybrid procedures.



Figure 4. After initial Hybrid Stage I palliation at 1 Kg, and later Comprehensive Stage II repair, eventual Fontan completion was performed around 2 years of age.

cardiothoracic surgeon, the cardiac interventionalist, as well as the echocardiographer. Intraoperative perventricular device closure of a MVSD was first reported in 1998.<sup>7</sup> Using this technique, cardiopulmonary bypass is not required. In a multi-center study, Bacha et al reported this technique in a large series of patients who underwent successful perventricular device closure of MVSD.<sup>8</sup> This approach has the advantage of avoiding or reducing time on cardiopulmonary bypass, avoiding a ventriculotomy, as well as resection of right ventricular muscle bundles. This technique is not limited in terms of patient weight or size, as no vascular access for device delivery or crossing multiple cardiac valves with a stiff cable are required (Figure 5a,b). When combining perventricular MVSD closure in conjunction with concomitant surgical repair of other complicated CHD utilizing partial flow on cardiopulmonary bypass, "under filling" of the heart may result in under-sizing the defect and ultimately the device. Under-sizing of the device may potentially result in embolization. Therefore, we recommend perventricular MVSD closure either before cardiopulmonary bypass has been initiated or after it is terminated and while the heart is filled.

#### Hybrid Intra-operative Stent Therapy

The cooperative relationship between the cardiothoracic surgeon and cardiac interventionalist in the operating room environment has also




Figure 5.(a) Perventricular MVSD closure is performed in a small infant through a median sternotomy off cardiopulmonary bypass. (b) A 10mm Amplatzer MVSD Occluder is successfully deployed.

led to Hybrid stent delivery to treat proximal and distal pulmonary artery stenoses in complex lesions such as repaired tetralogy of Fallot, repaired pulmonary atresia with VSD, repaired truncus arteriosus, and while undergoing surgical procedures such as RV-PA conduit or pulmonary valve replacement.<sup>9</sup> Stents can be placed under direct visualization using endoscopic camera guidance while on cardiopulmonary bypass (Figure 6). The endoscope can be introduced into the pulmonary artery and advanced to view side branches, as well as the area of stenosis. The distance can easily be measured on the endoscope to determine the appropriate stent length necessary to treat the lesion effectively without jailing any side branching. The proximal stent struts at the origin of the MPA can easily be crimped back to allow easy access into the branches during future cardiac catheterizations. In situations where cardiopulmonary bypass is not required, direct access is provided by the surgical team through a median sternotomy, or sometimes from a transthoracic needle puncture. Fluoroscopy and angiography are used in the procedures, either using a portable C-arm or a permanent x-ray system, as found in our Hybrid Cardiac Operating Suite. The Hybrid approach to PA stent therapy is beneficial in those patients with hypoplastic PA branches and who are at increased risk for vascular injury. Additionally, in patients without vascular access,





Figure 6. Endoscopic camera guidance is used in the Hybrid Cardiac Operating Suite to place intraoperative pulmonary artery stents while on cardiopulmonary bypass.



Figure 7. Exit angiography is routinely performed after Comprehensive Stage II repair for HLHS.

direct access into the main pulmonary artery is possible to treat branch or distal PA stenoses. There is no need for stiff wires and long sheaths. There is no difficulty tracking over guidewires and around curves or difficult outflow tracts. Also with direct visualization, the surgeon has better control in the event of a vascular complication.

### Hybrid Intraoperative Exit Angiography

Finally, in order to evaluate surgical repair or palliation of complex congenital heart disease, performing an "exit angiogram" is often helpful, especially in post-operative management or planning for future intervention. Performing an exit angiogram may identify a potential lesion which may benefit by treatment immediately in the operating suite versus just having awareness for future imaging (Figure 7). A complicated post-operative course and poor outcomes may be a result of residual structural pathology. Reports have



Figure 8. The RadPad is very useful for the surgeon during Hybrid procedures and exit angiography in order to provide shielding from radiation.

demonstrated that patients who required cardiac catheterization and intervention during the early post-operative course while in the ICU have increased mortality compared to patients who did not require cardiac catheterization.<sup>10</sup> Delaying cardiac catheterization post-operatively in patients with residual pathology has been identified as a significant risk factor for death.<sup>10</sup> Although Zahn and colleagues have reported that interventional therapy can be safely performed in the immediate post-operative period,<sup>11</sup> interventional therapy via a Hybrid approach in the O.R. with cardiopulmonary bypass readily available is a safer modality as opposed to a percutaneous intervention in the cardiac catheterization suite in a hemodynamically unstable post-op patient. Exit angiography can aid in identifying residual lesions which can be treated immediately while still on cardiopulmonary bypass in the operating suite. An angiographic catheter may be introduced directly through a suture line or purse string and advanced into position. Angiograms can be performed during low flow or off cardiopulmonary bypass. Holzer et al reviewed completion angiograms performed at Nationwide Children's Hospital in a specially designed Hybrid Cardiac Operating Suite and confirmed expected results in 47% of patients, while in 53% of patients unexpected abnormalities or residual lesions were identified.<sup>12</sup> As a result, 40% underwent Hybrid therapy during the surgery.

Radiation protection must be taken into consideration and available for the O.R. staff, especially for the surgeon who must remain at the table during fluoroscopy and digital acquisition. Sterile radiation protection pads are commercially available and can easily be clipped to the surgeon's sterile gown during the exit angiography procedure<sup>13</sup> (Figure 8). A limiting factor for the surgeon in a Hybrid Cardiac Catheterization Suite is the integrated table and the inability to perform all of the functions of a surgical table, including cradle roll to the right or left and reverse and trendelenberg motion. New technology has helped overcome this problem using the Toshiba® cradle table (Figure 9). This allows tilting of the table to accommodate the surgeon's field of vision, while also allowing steep RAO/LAO and even cranial projections where normally the C-arm would come in contact with the standard surgical table.

## OPPORTUNITY IN PEDIATRIC CARDIOLOGY CORPUS CHRISTI, TEXAS

Driscoll Children's Hospital is advancing a comprehensive Heart Center to meet the healthcare needs of congenital heart patients in South Texas. The Center is recruiting physicians with expertise in interventional cardiology or diagnostic imaging (i.e., echocardiography, TEE, and fetal). The Center also seeks cardiologists to support outpatient clinic activities, which include local and satellite facilities. Sub-specialty board eligible and/or certification is required for all positions. Advanced training or experience is preferred for clinical specialists. Clinical specialists will focus on their area of expertise and may participate in general and outpatient cardiology.

Pediatric Cardiology has been an integral part of Driscoll Children's Hospital since 1962. The Hospital and the Heart Center are committed to bringing state-of-the-art technology and quality service to 31 counties in South Texas. In 2009, the Heart Center saw 9,500 outpatient and satellite visits; 3,569 echocardiograms and 293 heart catheterizations (82% interventional). Driscoll Children's Hospital is associated with two pediatric cardio-thoracic surgeons who deliver all aspects of surgical service including hybrid procedures.

Corpus Christi and the Rio Grande Valley offer a relaxed "island style" setting with miles of Gulf beaches and mild weather perfect for outdoor activities. South Texas offers world class hunting, fishing, sailing and wind surfing. Golf, cycling and tennis are enjoyed year round. The cost of living in south Texas is low, and there is no state income tax.

**Interested applicants should send CV to:**

Roozbeh Taeed, MD  
Medical Director, Pediatric Cardiology  
(361) 694-5086

[Roozbeh.Taeed@dchstx.org](mailto:Roozbeh.Taeed@dchstx.org)

[www.driscollchildrens.org](http://www.driscollchildrens.org)

## References

1. Galantowicz M & Cheatham, JP. Lessons learned from the development of a new hybrid strategy for the management of hypoplastic left heart syndrome. *Pediatric Cardiology*, 2005;26(2): 190-199.
2. Galantowicz M, Cheatham JP, Phillips A, Cua CL, Hoffman TM, Hill SL, Rodeman R. Hybrid approach for hypoplastic left heart



Figure 9. The new Cradle Table allows the motion necessary for the cardiothoracic surgeon and is fully integrated into the biplane FPD Hybrid Cardiac Catheterization Suite.



Figure 10. Transapical balloon pulmonary valvuloplasty is performed in this critically ill 700 gram premature baby with poor RV function, ascites, and limited vascular access.

## The Future

This spirit of Hybrid collaboration has lead to performing cardiac procedures that were thought impossible years ago. Unusual cases include a transapical right ventricular approach to treat critical pulmonary valve stenosis in a 700gm, 24 week gestation neonate with RV failure, ascites, and no vascular access<sup>14</sup> (Figure 10); a placement of a ventricular pacemaker in a 550gm neonate with complex CHD and congenital atrioventricular heart block (Figure 11); and delivery of a customized covered stent to close a traumatic communication between the right innominate artery and the trachea in a 9-year-old presenting with life threatening hemoptysis (Figure 12 a,b). Hybrid therapy has even been transferred from the human population to "man's best friend" with equally outstanding results (Figure 13). All it takes is a spirit of collaboration, innovation, and team work. Oh yeah...and it doesn't hurt to have specially designed Hybrid Cardiac Catheterization and Operative Suites!





Figure 11. A 550 gram newborn with complete AV block and complex CHD presents challenges that are addressed in a Hybrid setting.

- syndrome: Intermediate results after the learning curve. The Annals of Thoracic Surgery, 2008;85(6):2063-70; discussion 2070-1.
3. Akinturk H, Michel-Behnke I, Valeske K, Mueller M, Thul J, Bauer J, Hagel KJ, Schranz D. Hybrid transcatheter-surgical palliation: Basis for univentricular or biventricular repair: The giessen experience. Pediatric Cardiology, 2007;28(2):79-87.
  4. Pilla CB, Pedra CA, Nogueira AJ, Jatene M, Souza LC, Pedra SR, Ferreiro C, Ricachinevsky CP, & Lucchese FA. Hybrid management for hypoplastic left heart syndrome: An experience from brazil. Pediatr Cardiol, 2008;29(3):498-506.
  5. Bacha E. Hybrid therapy for hypoplastic left heart syndrome: System-wide approach is vital. Pediatric Cardiology, 2008;29(3), 479-480.
  6. Bacha EA, Daves S, Hardin J, Abdulla RI, Anderson J, Kahana M, Koenig, Mora BN, Gulecyuz M, Starr, JP, Alboliras E, Sandhu S, Hijazi Z.M. Single-ventricle palliation for high-risk neonates: The emergence of an alternative hybrid stage I strategy. The Journal of Thoracic and Cardiovascular Surgery, 2006;131(1), 163-171.e2.
  7. Amin Z, Berry JM, Foker JE, Rocchini AP, Bass JL. Intraoperative closure of muscular ventricular septal defect in a canine model and application of the technique in a baby. J Thorac Cardiovasc Surg. 1998;115(6):1374-6.
  8. Bacha EA, Cao QL, Galantowicz ME, Cheatham JP, Fleishman CE, Weinstein SW, Becker PA, Hill SL, Koenig P, Albolira E, Abdulla R, Starr JP, Hijazi ZM. Multicenter experience with perventricular device closure of muscular ventricular septal defects. Pediatr Cardiol 2005;26, 169-17, 2005.
  9. Holzer RJ, Chisolm JL, Hill SL, Olshove V, Phillips A, Cheatham JP, Galantowicz M. "Hybrid" stent delivery in the pulmonary circulation. The Journal of Invasive Cardiology, 2008;20(11), 592-598.
  10. Asoh K, Hickey E, Dorostkar P et al. Outcomes of Emergent Cardiac Catheterization Following Pediatric Cardiac Surgery. [abstr]. Catheterization & Cardiovascular Interventions 2008;71:S5.
  11. Zahn EM, Dobrolet, NC, Nykanen DG, Ojito J, Hannan RL, Burke RP. Interventional catheterization performed in the early postoperative period after congenital heart surgery in children. J of the Amer Coll of Card 43(7):1264-9, 2004.
  12. Holzer R, Hill SL, Chisolm JL, Phillips A, Galantowicz M, Cheatham JP. Exit Angiography in a Dedicated 'Hybrid OR Suite'. – Initial Experience [abstr]. Catheterization & Cardiovascular Interventions 2008;71:Q21.
  13. Sawdy JM, Gocha MD, Olshove V et al. Radiation Protection during Hybrid Procedures: Innovation creates New Challenges. J of Invasive Cardiology 2009;21(9):437-40.



Figure 12. (a),(b) When a 9 year old presented with massive hemoptysis from erosion of a tracheostomy collar into the right innominate artery, the Hybrid team customized a covered stent to successfully close the erosion and control the bleeding.



Figure 13. After a call from the OSU Veterinary School Cardiology Department concerning a 7 month old Cavalier King Charles Spaniel that was in heart failure with a large MVSD, the combined Hybrid teams successfully placed a perventricular 18mm Amplatzer MVSD Occluder. "Sparky" was discharged within a few days and rejoined his family.



## CONGENITAL/PEDIATRIC ECHOCARDIOLOGIST

The Department of Pediatrics of the University Of Illinois College Of Medicine at Peoria (UICOMP) and Children's Hospital of Illinois (CHOI) seeks Pediatric ECHO Cardiology candidates who are board-certified or board-eligible in pediatric cardiology. Join a team of 7 pediatric cardiologists with 30 plus years of success in the region. Professional efforts will be bolstered by the support of 2 pediatric cardiovascular surgeons and a fully staffed cardiac intensive care unit with cardiac intensivists. In addition to general pediatric cardiology, opportunities focus on echocardiography, fetal echocardiography, and adult congenital disease.

### Other highlights:

- 5,000 echocardiograms (including transesophageal and fetal echos) last year.
- 200 catheterizations (60% interventional) and 175 pediatric cardiovascular surgeries last year.
- Associate Professor or Assistant Professor academic rank; Leadership role for qualified individual.
- Call of 1:6.
- A new, 8-story, 440,000 square foot Children's Hospital (to be completed in 2010) integrating all children's services within one building.
- Family-oriented community with a good school system, low crime rates, and a reasonable cost of living. Peoria is less than three hours from Chicago and St. Louis.

• UICOMP supports a thriving education program with approximately 21 pediatric residents and 32 medicine-pediatrics residents. UICOMP has 72 faculty members covering most pediatric subspecialties and primary care.

CHOI is the primary pediatric teaching facility for UICOMP and is a 127-bed facility that offers over 100 pediatric programs and services. CHOI is the only full service tertiary hospital for children in central Illinois with a designated Level I Trauma Center, a Regional Perinatal Center, and a Level III neonatal intensive care unit.

Please contact or send CV to: Marie Noeth at  
Ph: (309) 683-8350; Fax: (309) 683-8353;

[Marie.K.Noeth@osfhealthcare.org](mailto:Marie.K.Noeth@osfhealthcare.org); or [www.osfhealthcare.org](http://www.osfhealthcare.org)

*The University of Illinois is an Affirmative Action/Equal Opportunity employer.*

14. Holzer RJ, Sisk M, Phillips A. Hybrid Balloon Pulmonary Valvuloplasty in a 700-g Infant: Thinking Outside the Box Catheterization and Cardiovascular Interventions. 2008;72(1):93-96.

CCT

### Corresponding Author

Sharon L. Hill, MSN, ACNP-BC  
Interventional Nurse Practitioner  
Cardiac Catheterization & Interventional Therapy  
The Heart Center, Nationwide Children's Hospital  
The Ohio State University College of Nursing  
700 Children's Drive  
Columbus, OH 43205 USA  
Telephone: 614-722-6124 Fax: 614-722-5030

[sharon.hill@nationwidechildrens.org](mailto:sharon.hill@nationwidechildrens.org)

John P. Cheatham, MD, FSCAI  
Co-Director, The Heart Center  
Director, Cardiac Catheterization & Interventional Therapy  
Nationwide Children's Hospital  
Professor, Pediatrics & Internal Medicine, Cardiology  
The Ohio State University College of Medicine  
George H. Dunlap Endowed Chair in International Cardiology  
The Heart Center at Nationwide Children's Hospital  
700 Children's Drive  
Columbus, OH 43205 USA  
Phone: 713-500-5738; Fax: 713-500-5751

[John.Cheatham@NationwideChildrens.org](mailto:John.Cheatham@NationwideChildrens.org)

Ralf J. Holzer MD, MSc  
Cardiology  
The Heart Center at Nationwide Children's Hospital  
700 Children's Drive  
Columbus, OH 43205 USA

Alistair Phillips MD  
Cardiothoracic Surgery  
Nationwide Children's Hospital  
The Heart Center, Nationwide Children's Hospital  
700 Children's Drive  
Columbus, OH 43205 USA

Mark Galantowicz, MD  
Co-Director, The Heart Center  
Chief, Cardiothoracic Surgery  
Nationwide Children's Hospital  
Associate Professor of Surgery  
The Ohio State University College of Medicine  
Murray D. Lincoln Endowed Chair in Cardiothoracic Surgery  
The Heart Center, Nationwide Children's Hospital  
700 Children's Drive  
Columbus, OH 43205 USA

Pediatric & Congenital Rhythm Congress

September 22-25th, 2010 | Çeşme-Izmir, Turkey

[www.pedirhythm.org](http://www.pedirhythm.org)

A comprehensive update on Pediatric Rhythm Management





Melody® Transcatheter Pulmonary Valve  
Ensemble® Transcatheter Valve Delivery System

**Indications for Use:**

The Melody TPV is indicated for use as an adjunct to surgery in the management of pediatric and adult patients with the following clinical conditions:

- Existence of a full (circumferential) RVOT conduit that was equal to or greater than 16 mm in diameter when originally implanted and
- Dysfunctional RVOT conduits with a clinical indication for intervention, and either:
  - regurgitation:  $\geq$  moderate regurgitation, or
  - stenosis: mean RVOT gradient  $\geq$  35 mm Hg

**Contraindications:** None known.

**Warnings/Precautions/Side Effects:**

- DO NOT implant in the aortic or mitral position. Preclinical bench testing of the Melody valve suggests that valve function and durability will be extremely limited when used in these locations.
- DO NOT use if patient's anatomy precludes introduction of the valve, if the venous anatomy cannot accommodate a 22-Fr size introducer, or if there is significant obstruction of the central veins.
- DO NOT use if there are clinical or biological signs of infection including active endocarditis.
- Assessment of the coronary artery anatomy for the risk of coronary artery compression should be performed in all patients prior to deployment of the TPV.
- To minimize the risk of conduit rupture, do not use a balloon with a diameter greater than 110% of the nominal diameter (original implant size) of the conduit for pre-dilation of the intended site of deployment, or for deployment of the TPV.
- The potential for stent fracture should be considered in all patients who undergo TPV placement. Radiographic assessment of the stent with chest radiography or fluoroscopy should be included in the routine postoperative evaluation of patients who receive a TPV.
- If a stent fracture is detected, continued monitoring of the stent should be performed in conjunction with clinically appropriate hemodynamic assessment. In patients with stent fracture and significant associated RVOT obstruction or regurgitation, reintervention should be considered in accordance with usual clinical practice.

Potential procedural complications that may result from implantation of the Melody device include: rupture of the RVOT conduit, compression of a coronary artery, perforation of a major blood vessel, embolization or migration of the device, perforation of a heart chamber, arrhythmias, allergic reaction to contrast media, cerebrovascular events (TIA, CVA), infection/sepsis, fever, hematoma, radiation-induced erythema, and pain at the catheterization site.

Potential device-related adverse events that may occur following device implantation include: stent fracture resulting in recurrent obstruction, endocarditis, embolization or migration of the device, valvular dysfunction (stenosis or regurgitation), paravalvular leak, valvular thrombosis, pulmonary thromboembolism, and hemolysis.

For additional information, please refer to the Instructions for Use provided with the product.

**CAUTION:** Federal law (USA) restricts this device to sale by or on the order of a physician.

Melody and Ensemble are registered trademarks of Medtronic, Inc.



**Medtronic**

# Hope, Restored.

A revolutionary treatment option designed to delay the need for surgical intervention.

Restore hope for your patients with RVOT conduit dysfunction.

[www.Melody-TPV.com](http://www.Melody-TPV.com)



**Melody®**

TRANSCATHETER PULMONARY VALVE (TPV) THERAPY

**Humanitarian Device.** Authorized by Federal law (USA) for use in pediatric and adult patients with a regurgitant or stenotic Right Ventricular Outflow Tract (RVOT) conduit ( $\geq$  16 mm in diameter when originally implanted). The effectiveness of this device for this use has not been demonstrated.

# Abstracts from “Evolving Concepts in the Management of Complex Congenital Heart Disease II” - Part IV

*“Abstracts from ‘Evolving Concepts in the Management of Complex Congenital Heart Disease II’ - Part IV” includes the following topics and presenters:*

- When MRI, When CT by Beth Feller Printz, MD, PhD
- Indications for AICD, Anti-Tachycardia PM, Bi-V Pacing by Kevin Shannon, MD
- Is the Fontan Procedure Different in HLHS versus Other Single Ventricles? by Thomas L. Spray, MD

*Read Parts I, II and III in the April, May and June issues of Congenital Cardiology Today. Read Part V in the upcoming August Issue*



**Abstract Title:** When MRI, When CT  
**Presenter:** Beth Feller Printz, MD, PhD  
Medical Director, Non-Invasive Cardiac Imaging, Division of Cardiology, Rady Children's Hospital - San Diego, San Diego, CA USA

## Objectives

1. Review the strengths and weaknesses of cardiac MRI (CMR) when compared with cardiac and thoracic CT for the evaluation of children and young adults with congenital and acquired heart disease.
2. Discuss relative 'costs' of CT vs. CMR.
3. Review potential future applications of these imaging modalities for the evaluation and treatment of congenital heart disease.

## Abstract

Although echocardiography has become the mainstay of non-invasive imaging for children and young adults with congenital and acquired heart disease, there are many instances when echocardiography is insufficient to fully characterize cardiac and thoracic anatomy and physiology. Cardiac MRI (CMR) and CT have both become important imaging techniques as adjuncts not only to echocardiography, but also to cardiac catheterization and radionuclide imaging in these patients.<sup>1,2</sup> For example, both CMR and CT can evaluate complex anatomic relations in any imaging plane, as they are both 3-D tomographic techniques. CMR phase-contrast flow imaging can be used to accurately measure pulmonary and systemic blood flow for shunt assessments, to determine valvar regurgitation (for example, to quantify pulmonary regurgitation following Tetralogy of Fallot repair), and to assess

differential pulmonary perfusion as an alternate to radionuclide perfusion imaging. CMR can also be used to assess myocardial viability, both at rest and with stress, which may be particularly helpful in evaluating patients who have undergone surgical repair of congenital heart disease, or in those patients with 'acquired' cardiac pathology such as cardiomyopathy or myocarditis. Hybrid CMR technology is also being pioneered for interventional cardiac procedures, in part to decrease exposure to ionizing radiation, but also to take advantage of CMR's strengths.<sup>3</sup>

CMR, however, can be a time-consuming procedure and requires sedation or anesthesia in most young children. At present, cardiac MRI cannot be performed in patients with pacemakers; the presence of ferro-magnetic coils or stents can also preclude diagnostic-quality imaging. Cardiac CT can be obtained in much less time, potentially obligating the need for sedation or anesthesia; also, CT is not as sensitive to artifacts from metallic implants and can be performed in patients following pacemaker insertion. Another advantage of CT is that its spatial resolution can be superior to what can be obtained using many commercially-available CMR platforms, leading to improved coronary artery imaging. Cardiac CT may also be a less 'expensive' test vis a vis monetary charges billed. These advantages of cardiac CT are tempered by the risk of radiation exposure, particularly in young children who are more sensitive to the effects of radiation or in those subjects where serial scans are required.<sup>4,5</sup> Recent advances in multi-detector CT technology can significantly decrease radiation exposure and make cardiac CT a feasible alternative to CMR in select cases.

## References

1. Krishnamurthy R. The role of cardiac MRI and CT in congenital heart disease. *Pediatric Radiology* 2009; 39 (suppl 2):S196-S204.
2. Chan FP. MR and CT imaging of the pediatric patient with structural heart disease. *Seminars in Thoracic Cardiovascular Surgery Annual* 2009:99-105.
3. Ratnayaka K, Faranesh AZ, Guttman MA, Kocaturk O, Saikus CE, Lederman RJ. Interventional cardiovascular magnetic resonance: still tantalizing. *Journal of Cardiovascular Magnetic Imaging* 2008; 10: 62.
4. Brenner and Hall. Computed tomography – an increasing source of radiation exposure. *New England Journal of Medicine* 2007;357:2277-84
5. Huang B, Law MW, Mak HK, Kwok SP, Khong PL. Pediatric 64-MDCT coronary angiography with ECG-modulated tube current: radiation dose and cancer risk. *AJR: American Journal of Roentgenology* 2009;193:539-44.

CCT







**Abstract Title:** Indications for AICD, Anti-Tachycardia PM, Bi-V Pacing  
**Presenter:** Kevin Shannon, MD; Director, Pediatric Electrophysiology Program; Mattel Children's Hospital, Division of Pediatric Cardiology; Los Angeles, CA, USA

- ICD therapy is indicated in patients with a LVEF <35% due to prior myocardial infarction who are 40 days post-myocardial infarction and in New York Heart Association (NYHA) functional class II or III.
- ICD therapy is indicated in patients with a LVEF <35% due to nonischemic dilated cardiomyopathy who are in NYHA functional class II or III.
- ICD therapy is indicated in patients with a LVEF <30% due to prior myocardial infarction who are 40 days post-myocardial infarction and in NYHA functional class I.

## Objective

- Discuss published guidelines and controversies in device therapy for congenital heart disease.
- Review indications for ICD placement in patients with congenital heart disease.
- Review efficacy and complication data in patients with congenital heart disease who receive ICD's.
- Review available data on safety and efficacy of antitachycardia pacing in congenital heart disease.
- Review indications for biventricular pacing.
- Review safety and efficacy data on biventricular pacing in patients with congenital heart disease.

## Abstract

Implantable Cardioverter-Defibrillator therapy in congenital heart disease.

Data from studies in adult patients with ischemic cardiomyopathy and idiopathic dilated cardiomyopathy have consistently shown a survival benefit in patients undergoing ICD implantation, if they met symptom and ejection fraction criteria. These findings have led to the development of the following criteria for implantation of ICD in this patient population:

The annual sudden death-rate in the patient populations studied were 6-11 %. Sudden death rates in patients with congenital heart disease and ventricular dysfunction are substantially lower, and thus, the efficacy of ICD placement may not be as high. The incidence of inappropriate shocks is as high as 20% in most studies of patients with congenital heart disease, with a similar incidence of complications resulting in the need for re-operation. These factors suggest that the criteria for ICD implantation in younger patients with congenital heart disease should be more stringent than the current guidelines for adult patients with ischemic or idiopathic cardiomyopathy.

### Anti-tachycardiac pacing.

Atrial antitachycardia pacing has limited availability, and is of limited utility. Cardiac catheter ablation has become the treatment of choice for most patients with a single tachycardia circuit and uncomplicated atrial tachycardia. Patients with complex heart disease tend to have multiple atrial tachycardia substrates, and as a consequence, have limited efficacy with antitachycardia pacing. Patient activated therapies and antitachycardia pacing on an ICD platforms may improve the utility of this therapy.

## PEDIATRIC CARDIOLOGY

**Geisinger Health System is seeking a BC/BE Pediatric Cardiologist to join its collaborative team of 4 Pediatric Cardiologists and 1 Pediatric Cardiovascular Surgeon at Geisinger's Janet Weis Children's Hospital, an exceptional tertiary referral center, located on the campus of Geisinger Medical Center in Danville, PA.**

This position involves working within a large multidisciplinary group, providing inpatient care in our children's hospital and outpatient care locally and at outreach locations. It provides opportunities to practice state-of-the-art medicine, teach students and residents, benefit from a fully digital echo system, and work with others providing comprehensive advanced cardiac care. Research opportunities are available.

**Janet Weis Children's Hospital** is a dedicated children's hospital within a hospital, with an ICAEL-certified Echocardiography laboratory, an

advanced cardiac imaging center, an Interventional Cardiac Catheterization program, ECMO, a 12-bed PICU and a 38-bed Level III NICU, with all sub-specialties well represented.

**Geisinger Health System** serves nearly 3 million people in Northeastern and Central Pennsylvania and is nationally recognized for innovative practices and quality care. A mature electronic health record connects a comprehensive network of 2 hospitals, 38 community practice sites and more than 700 Geisinger primary and specialty care physicians.

For more information or to apply for this position, please contact:  
**Robert Mangano, MD, c/o**  
**Kathy Kardisco, Department**  
**of Professional Staffing,**  
**at 1-800-845-7112,**  
**email:**  
**kkardisco@geisinger.edu**



**Learn more at [Join-Geisinger.org/150/PedCard](http://Join-Geisinger.org/150/PedCard)**

**GEISINGER**  
**Janet Weis Children's Hospital®**



The University of Maryland Hospital for Children is developing a comprehensive Children's Heart Center to meet the cardiovascular healthcare needs of the children of Maryland. We are currently recruiting for a variety of faculty positions. Sub-specialty board certification or equivalent work experience is required for each position. Clinical duties will focus primarily in the respective field of each position and participate to varying degrees in the general pediatric cardiology and outpatient practices. The Children's Heart Center supports integrated quality enhancement and clinical research practices to improve patient outcomes and patient/family experience.

The successful candidates will have faculty appointments in the Department of Pediatrics of the University of Maryland School of Medicine at academic levels to be determined by experience. The University of Maryland Medical Center is a major academic tertiary care center serving Baltimore, the state of Maryland, and the mid-Atlantic region. As the oldest public medical school in the United States, the University of Maryland School of Medicine has an established tradition of outstanding clinical care, education, and research. The Department of Pediatrics is deeply committed to promoting children's health in the community and across the state, while supporting innovative clinical programs and expanding research initiatives.

Located on the modern and urban campus of the University of Maryland at Baltimore, The School of Medicine is one of seven professional schools within the University of Maryland system. The campus is ideally located within walking distance to the Baltimore Inner Harbor, National Aquarium, Baltimore Convention Center, Hippodrome Theatre, Orioles Park at Camden Yards and Baltimore Ravens M & T Bank Stadium. The University of Maryland Hospital for Children is also close to Historic Annapolis, the Chesapeake Bay, Washington DC, and many residential communities with outstanding public and private schools. The area offers rich cultural fabric and many unique recreational opportunities. The University of Maryland is an EOE/AA/ADA and encourages minorities to apply.

Interested applicants should send CV to:

Dr. Geoffrey L. Rosenthal  
Director, Pediatric & Congenital Heart Program  
University of Maryland Hospital for Children  
22 S. Greene Street, N5W68  
Baltimore, MD 21201

[grosenthal@peds.umaryland.edu](mailto:grosenthal@peds.umaryland.edu)

[WWW.UMM.EDU/PEDIATRICS](http://WWW.UMM.EDU/PEDIATRICS)

## Biventricular pacing

Several retrospective studies have shown that biventricular or multisite pacing can improve cardiac function and alleviate heart failure symptoms in patients with congenital heart disease, including patients with univentricular heart disease and systemic morphologic right ventricles. The patients most likely to benefit appear to be those with a deterioration in cardiac function related to single site pacing. Criteria for identifying likely responders and or non-responders need to be improved, as do techniques for identifying and accessing ideal pacing sites.

## References

1. Should patients with congenital heart disease and a systemic ventricular ejection fraction less than 30% undergo prophylactic implantation of an ICD? Implantable cardioverter defibrillator implantation guidelines based solely on left ventricular ejection fraction do not apply to adults with congenital heart disease. Triedman JK. *Circ Arrhythm Electrophysiol.* 2008 Oct;1(4):307-16;
2. Should patients with congenital heart disease and a systemic ventricular ejection fraction less than 30% undergo prophylactic implantation of an ICD? Patients with congenital heart disease and a systemic ventricular ejection fraction less than 30% should undergo prophylactic implantation of an implantable cardioverter defibrillator. Silka MJ, Bar-Cohen Y. *Circ Arrhythm Electrophysiol.* 2008 Oct;1(4):298-306
3. Efficacy of atrial antitachycardia pacing using the Medtronic AT500 pacemaker in patients with congenital heart disease. Stephenson EA, Casavant D, Tuzi J, Alexander ME, Law I, Serwer G, Strieper M, Walsh EP, Berul CI; ATTEST Investigators. *Am J Cardiol.* 2003 Oct 1;92(7):871-6.
4. Antitachycardia pacing. Gillette PC. *Pacing Clin Electrophysiol.* 1997 Aug;20(8 Pt 2):2121-4.
5. Resynchronization therapy in pediatric and congenital heart disease patients: an international multicenter study. Dubin AM, Janousek J, Rhee E, Strieper MJ, Cecchin F, Law IH, Shannon KM, Temple J, Rosenthal E, Zimmerman FJ, Davis A, Karpawich PP, Al Ahmad A, Vetter VL, Kertesz NJ, Shah M, Snyder C, Stephenson E, Emmel M, Sanatani S, Kanter R, Batra A, Collins KK. *J Am Coll Cardiol.* 2005 Dec 20;46(12):2277-83.

## CCT



**Abstract Title:** Is the Fontan Procedure Different in HLHS versus Other Single Ventricles?

**Presenter:** Thomas L. Spray, MD; Chief, Division of Cardiothoracic Surgery; Children's Hospital of Philadelphia, Philadelphia, PA USA

## Objective

To analyze the results with Fontan surgery for single ventricle malformations and the potential long-term effects of a right ventricle as the systemic ventricle.

SPECIALTY  
REVIEW IN **Pediatric  
Cardiology**  
OCTOBER 11-15, 2010 • CHICAGO

**A BOARD REVIEW COURSE PRESENTED BY  
American Academy of Pediatrics Section on Cardiology & Cardiac Surgery  
— in collaboration with —**

**Society of Pediatric Cardiology Training Program Directors**

*Discounts for early registration and AAP section members available.*

[http://aap.org/sections/cardiology/pediatric\\_cardiology](http://aap.org/sections/cardiology/pediatric_cardiology)



## Abstract

As larger numbers of patients are undergoing the Fontan operation for variants of Hypoplastic Left Heart Syndrome (HLHS) with a single right ventricle as the systemic ventricular mass, there is increasing interest in the longevity of the right ventricle as the systemic ventricle in the Fontan circulation. Most infants undergo a series of staged reconstruction operations beginning in the neonatal period and culminating at an eventual Fontan procedure. The goals of neonatal management include creation of unobstructed systemic outflow and pulmonary venous pathways, limitation of pulmonary blood flow and avoidance of pulmonary artery distortion. A variety of technical modifications have been introduced over the years, including staging with an interim superior cavopulmonary connection, use of an intra-atrial baffle to create a lateral tunnel Fontan, creation of an intentional right-to-left shunt (fenestration), and introduction of the extracardiac conduit Fontan. Because of improved management in the neonatal period in early infancy an increasing number of patients previously thought to be at high risk, especially those with HLHS, are now being referred for the Fontan operation. Despite this very dramatic change in patient population there has been a dramatic reduction in mortality and morbidity after the Fontan operation.

Although reports from some centers have suggested that Hypoplastic Left Heart Syndrome is a risk factor for survival after the Fontan procedure, our own experience at The Children's Hospital of Philadelphia has not been able to identify the presence of a systemic right ventricle as a significant risk factor for Fontan survival. In a series of 332 Fontan patients from January 1, 1992 to December 31, 1999, including a large percentage of patients with HLHS, systemic ventricular morphology had no effect on overall outcome. Similar results have been reported from the group at The University of Michigan where anatomy also was not a significant factor in overall survival. At interim staging with the bidirectional cavopulmonary anastomosis there has been no obvious influence of ventricular anatomy on survival, although A-V valve regurgitation seems to be an independent risk factor for death or transplantation. Whether A-V valve regurgitation is associated with a single right ventricle versus a left ventricle was not independently evaluated. Even when performed at elevated altitude where pulmonary resistance might effect overall survival, no influence of ventricular morphology on survival was identified in a series from Denver Children's Hospital. Ventricular morphology also did not turn out to be a significant predictor of exercise performance in the first two decades of life after the Fontan operation.

Evaluation of neurodevelopmental outcome after the Fontan operation also has not consistently shown a difference between right and left ventricular morphology or that patients with HLHS drome was an independent risk factor for low achievement scores, however, other studies from Michigan have not identified any difference in patients with HLHS as have the studies at The Children's Hospital of Philadelphia.

In summary, a review of the reported series of Fontan operations in patients with single ventricle anatomy have not been able to identify ventricular anatomy as an independent risk factor for outcome. However, the increasing number of patients with HLHS now coming to the Fontan operation with now longer survival times may ultimately show a decrease in longevity in patients with a systemic right ventricle as has been seen in patients with the atrial switch operation

for transposition. It is conceivable however that the late problems with the Fontan circulation are less related to ventricular morphology than to primary problems with the pulmonary vascular bed or diastolic function of the ventricles rather than purely ventricular morphologic anatomy. An increasing attention to methods for treating late Fontan failure will be necessary to deal with these patients as they age.

## References

- Scheurer, MA, Hill, EG, Vasuki, N, Maurer, S, Graham, EM, Bandisode, V, Shirali, GS, Atz, AM, and Bradley, SM. Survival after bidirectional cavopulmonary anastomosis: Analysis of preoperative risk factors. *J Thorac Cardiovasc Surg* 2007;134(1):82-89.e2.
- Gaynor JW, Bridges ND, Cohen MI, Mahle WT, DeCampi WM, Steven JM, Nicolson SC, and Spray TL. Predictors of outcome after the Fontan operation: Is hypoplastic left heart syndrome still a risk factor? *J Thorac Cardiovasc Surg* 2002; 123(2):237-245.
- Malhotra, SP, Ivy, DD, Mitchell, MB, Campbell, DN, Dines, ML, Miyamoto, S, Kay, J, Clarke, DR, Lacour-Gayet, F. Performance of cavopulmonary palliation at elevated altitude. Midterm outcomes and risk factors for failure. *Circ* 2008; 118(suppl 1):S177-S181.
- Paridon, SM, Mitchell, PD, Colan, SD, Williams, RV, Blaufox, A, Li, JS, Margossian, R, Mital, S, Russell, J, Rhodes, J. A cross-sectional study of exercise performance during the first 2 decades of life after the Fontan operation. *J Amer Coll Card* 2008; 52(2): 99-107.
- Hirsch, JC, Goldberg, C, Bove, EL, Salehian, S, Lee, T, Ohye, RG, Devaney, EJ. Fontan operation in the current era. A 15-year single institution experience. *Ann Surg* 2008;248(3):402-410.
- Gentles, TL, Mayer, JE, Gauvreau, K, Newburger, JW, Lock, JE, Kupferschmid, JP, Burnett, J, Jonas, RA, Castaneda, AR, Wernovsky, G. Fontan operation in five hundred consecutive patients: Factors influencing early and late outcome. *J Thorac Cardiovasc Surg* 1997; 114(3):376-391.
- Wernovsky, G, Stiles, KM, Gauvreau, K, Gentles, TL, duPlessis, AJ,
- Bellinger, DC, Walsh, AZ, Burnett, J, Jonas, RA, Mayer, JE, Newburger, JW. Cognitive development after the Fontan operation. *Circ* 2000; 102:883-889.
- Goldberg, CS, Schwartz, EM, Brunberg, JA, Mosca, RS, Bove, EL, Schork, MA, Stetz, SP, Cheatham, JP, Kulik, TJ. Neurodevelopmental outcome of patients after the Fontan operation: A comparison between children with Hypoplastic Left Heart Syndrome and other functional single ventricle lesions. *J Peds* 2000, 137(5):646-652.

CCT

**Do you or your colleagues have interesting research results, observations, human interest stories, reports of meetings, etc. that you would like to share with the congenital cardiology community?**

Submit article to Congenital Cardiology Today at:  
[RichardK@CCT.bz](mailto:RichardK@CCT.bz)

The final manuscript may be between 400-4,000 words, and contain pictures, graphs, charts and tables.



IMAGING IN CONGENITAL AND STRUCTURAL  
CARDIOVASCULAR INTERVENTIONAL THERAPIES  
**ONE DAY SYMPOSIUM**  
IMMEDIATELY PRECEEDING PICS-AICS



# Medical News, Products and Information

## Edwards Lifesciences Announces Receipt of CE Mark for Pulmonic Transcatheter Valve

IRVINE, CA--(Marketwire - May 26, 2010) - Edwards Lifesciences Corporation, a global leader in the science of heart valves and hemodynamic monitoring, announced on May 26, 2010, the receipt of CE Mark for the Edwards SAPIEN pulmonic transcatheter heart valve. The valve is designed to be an alternative to surgical valve replacement for patients suffering from congenital heart disease of the pulmonic valve and leverages the company's transcatheter valve technology, which has been used in more than 5,000 cases around the world.

"The Edwards SAPIEN pulmonic transcatheter heart valve gives clinicians the potential to eliminate one of the multitude of open-chest procedures that their young congenital heart patients will face in their lifetimes," said Ziyad M. Hijazi, MD, MPH, Director of the Rush Center for Congenital and Structural Heart Disease, Chief of Pediatric Cardiology and Professor in the Departments of Pediatrics and Internal Medicine at Rush University, Chicago. "As every re-operation increases a patient's risk of infection, illness and death, it is a gift to have a minimally invasive way to treat these fragile patients."

"We are proud to apply our extensive experience in heart valve innovation and leadership in transcatheter technology to provide a high-quality solution for patients with so many unmet needs," said Larry L. Wood, Edwards' Corporate VP, Transcatheter Valve Replacement.

The Edwards SAPIEN pulmonic transcatheter valve's leaflet design is modeled after Edwards' clinically proven aortic tissue valves and its stainless steel frame provides high radial strength. Prior to delivery, the bovine pericardial tissue valve is compressed onto a balloon to the approximate diameter of a pencil. It is then threaded through the patient's circulatory system using the RetroFlex 3 transfemoral delivery system, which enables accurate deployment of the valve across the patient's pulmonary valve.

In the US, this valve is an investigational device currently being studied in the COMPASSION (COngenital Multicenter trial of Pulmonic vAlve regurgitation Studying the SAPIEN IntervEntIONAL THV) clinical trial, which will assess the safety of the valve. The company completed its feasibility study of the valve and is

progressing into the pivotal portion of the clinical trial with the goal of receiving a Humanitarian Device Exemption from the US Food and Drug Administration.

Dr. Hijazi is the principal investigator of the COMPASSION clinical trial and a consultant to Edwards for education and research.

Additional company information can be found at [www.edwards.com](http://www.edwards.com).



## BE/BC Pediatric Cardiologist

The Section of Cardiology at Children's Mercy Hospitals & Clinics-Kansas City is actively looking for a BE/BC Pediatric Cardiologist with a desire to work with professionals in a supportive environment committed to excellence in patient care. Training and expertise in fetal echocardiography, non-invasive diagnostic imaging, including transthoracic, transesophageal, and 3-D echocardiography are necessary.

This physician will join a team of 13 boarded Pediatric Cardiologists, 5 Nurse Practitioners, and 2 Exercise Physiologists. Our section, with support from nursing, social work, nutrition and exercise physiology, offers the region's most comprehensive care for newborns to young adults with congenital or acquired heart disease. Through our Ward Family Center for Congenital Heart Disease, we collaborate with cardiac surgeons and other specialists to offer enhanced treatment and research opportunities for children and adults with congenital heart disease. As a training site for University of Missouri-Kansas City, Children's Mercy physicians integrate education and teaching into all aspects of patient care. This training is to residents, fellows, medical and nursing students. Research is encouraged and supported in an environment rich with opportunities.

EOE/AAP

### Contact us:

R. Gowdamarajan, MD  
SECTION CHIEF  
Children's Mercy Hospitals and Clinics  
Kansas City, Missouri

PHONE: 866-264-4652

EMAIL: [physicianjobs@cmh.edu](mailto:physicianjobs@cmh.edu)

[www.childrensmercy.org](http://www.childrensmercy.org)

## CONGENITAL CARDIOLOGY TODAY

© 2010 by Congenital Cardiology Today  
(ISSN 1554-7787-print; ISSN 1554-0499-online). Published monthly. All rights reserved.

### Headquarters

824 Elmcroft Blvd.  
Rockville, MD 20850 USA

### Publishing Management

Tony Carlson, Founder & Senior Editor

[TCarlsonmd@gmail.com](mailto:TCarlsonmd@gmail.com)

Richard Koulbanis, Publisher & Editor-in-Chief

[RichardK@CCT.bz](mailto:RichardK@CCT.bz)

John W. Moore, MD, MPH, Medical Editor/  
Editorial Board

[JMoore@RCHSD.org](mailto:JMoore@RCHSD.org)

### Editorial Board

Teiji Akagi, MD; Zohair Al Halees, MD; Mazeni Alwi, MD; Felix Berger, MD; Fadi Bitar, MD; Jacek Bialkowski, MD; Philipp Bonhoeffer, MD; Mario Carminati, MD; Anthony C. Chang, MD, MBA; John P. Cheatham, MD; Bharat Dalvi, MD, MBBS, DM; Horacio Faella, MD; Yun-Ching Fu, MD; Felipe Heusser, MD; Ziyad M. Hijazi, MD, MPH; Ralf Holzer, MD; Marshall Jacobs, MD; R. Krishna Kumar, MD, DM, MBBS; Gerald Ross Marx, MD; Tarek S. Momenah, MBBS, DCH; Toshio Nakanishi, MD, PhD; Carlos A. C. Pedra, MD; Daniel Penny, MD; James C. Perry, MD; P. Syamasundar Rao, MD; Shakeel A. Qureshi, MD; Andrew Redington, MD; Carlos E. Ruiz, MD, PhD; Girish S. Shirali, MD; Horst Sievert, MD; Hideshi Tomita, MD; Gil Wernovsky, MD; Zhuoming Xu, MD, PhD; William C. L. Yip, MD; and Carlos Zabal, MD

### FREE Subscription

Congenital Cardiology Today is available free to qualified professionals worldwide in pediatric and congenital cardiology. International editions available in electronic PDF file only; North American edition available in print. Send an email to [Subs@CCT.bz](mailto:Subs@CCT.bz). Include your name, title, organization, address, phone and email.

### Contacts and Other Information

For detailed information on author submission, sponsorships, editorial, production and sales contact, current and back issues, see website or send an email to: [INFO@CCT.bz](mailto:INFO@CCT.bz).





# Your Search Ends Here.



1301 Concord Terrace  
Sunrise, Florida 33323

Pediatrix Cardiology is a national provider of outpatient and inpatient cardiology care of the fetus, infant, child and adolescent, as well as adults with congenital heart disease.

We have an opportunity for you, whether you're a recent graduate looking to gain experience or a seasoned pediatric cardiologist seeking a leadership role. With a wide variety of services and a presence in several states, you can choose the practice environment and location that best suits you.

We offer competitive salaries and excellent benefits including health (choice of two PPO options), life, vision, dental and disability insurance; 401(k) with potential company percentage match; annual CME allowance; potential for relocation assistance; employee stock purchase plan; stability in an organization with more than 30 years of health care industry experience; opportunities to participate in clinical quality improvement initiatives and clinical research; professional liability insurance; and assistance with mandatory hospital credentialing and state licensing, and reimbursement of associated fees.

More than 90 pediatric cardiologists have chosen to join our team to pursue their personal and professional goals. Now it's your turn.

Please contact us to learn more about pediatric cardiology positions in:

Fort Lauderdale, Florida Area • Springfield, Missouri • Albuquerque, New Mexico  
Dallas, Texas • San Antonio, Texas • Fairfax, Virginia

800.243.3839, ext. 6511  
[www.pediatrix.com/cardijobsnow](http://www.pediatrix.com/cardijobsnow)



# TINY HEARTS INSPIRED HYBRID LABS WITH ACCESS FOR BIG TEAMS.

Fixing a heart from birth through adulthood takes big teams working together. So we examined the needs of leading clinicians when designing our hybrid solutions. The result: our Infinix™-i with 5-axis positioners and low profile detectors, stays out of the way, but right where needed, providing the best possible access to patients. To lead, you must first listen.

[medical.toshiba.com](http://medical.toshiba.com)

**TOSHIBA**  
Leading Innovation >>>